Fructose-induced fatty liver disease: Hepatic effects of blood pressure and plasma triglyceride reduction

Hypertension

Volumn 45, Issue 5, 2005, Pages 1012-1018

  Ackerman, Zvi ^a,e   Oron Herman, Mor ^b,c   Grozovski, Maria ^f   Rosenthal, Talma ^b   Pappo, Orit ^a,e   Link, Gabriela ^d,e   Sela, Ben Ami ^b,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d Dept of Human Nutrition/Metabolism ^*  (Israel)

^e HEBREW UNIVERSITY   (Israel)

^f ORT BRAUDE COLLEGE   (Israel)

Author keywords

Amlodipine; Bezafibrate; Captopril; Iron; Nonalcoholic steatohepatitis

Indexed keywords

AMLODIPINE; BEZAFIBRATE; CAPTOPRIL; FRUCTOSE; IRON; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; FATTY LIVER; HEMOCHROMATOSIS; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; IRON OVERLOAD; LIPID COMPOSITION; LIVER PARENCHYMA; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RISK FACTOR;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BEZAFIBRATE; BLOOD PRESSURE; CAPTOPRIL; DIET; FATTY LIVER; FRUCTOSE; IRON; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 18244375243     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000164570.20420.67     Document Type: Article

References (53)

1. Sanyal AJ. AGA technical review on non-alcoholic fatty liver disease. Gastroenterology. 2002;123:1705-1725.
2. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
3. Green RM. NASH-Hepatic metabolism and not simply the metabolic syndrome. Hepatology. 2003;38:14-17.
4. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Non-alcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology. 2003;37:917-923.
5. Chitturi S, Abeygunesekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance, insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-379.
6. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Non-alcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-1192.
7. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo F, Faga F, Silli B, Pagono G. Dietary habits and their relations to insulin resistance and postprandial lipemia in non-alcoholic steatohepatitis. Hepatology. 2003;37:909-916.
8. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology. 1999;30:1356-1362.
9. Bacon RB, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: An expanded clinical entity. Gastroenterology. 1994;107:1103-1109.
10. Day CP, James OFW. Steatohepatitis: A tale of two "hits"? Gastroenterology. 1998;114:842-845.
11. Fischer JG, Glauert HP, Yin T, Sweeney-Reeves ML, Larmonier N, Black MC. Moderate iron overload enhances lipid peroxidation in livers of rats but does not affect NF-KB activation induced by the peroxisome proliferation Wy-14,643. J Nutr. 2002;132:2525-2531.
12. Tsukamoto H, Horne W, Kamimura S, Niemela O, Parkkila S, Yla-Herttuala S, Brittenham GM. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 1995;96;620-630.
13. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: A study of 447 native livers. Gastroenterology. 1997;112:882-888.
14. Cotler SJ, Bronner MP, Press RD, Carlson TH, Perkins JD, Emond MJ, Kowdley KV. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol. 1999;29:257-262.
15. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 1988;114:311-318.
16. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JV, Brissot P, David V, Deugnier Y. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999;117:1155-1163.
17. Fernández-Real JM, Penarroja G, Gastro A, Garcia-Brazado F, Hernández-Aguado I, Ricant W. Blood letting in high ferritin type 2 diabetes. Effects on insulin sensitivity and beta-cell function. Diabetes. 2002;41:1000-1004.
18. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of non-alcoholic fatty liver disease. Gastroenterology. 2002;122:931-939.
19. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner B. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol. 1999;31:421-429.
20. Vigano M, Vergani A, Trombini P, Pozzi M, Paleari F, Piperno A. Insulin resistance influences iron metabolism and hepatic steatosis in type II diabetes. Gastroenterology. 2000;118:986-987.
21. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and non-alcoholic fatty liver disease. Hepatology. 1999;30:847-850.
22. Chitturi S, Weltman M, Farrell GC, McDonald D, Liddle C, Samarasingbe D, Lin R, Abeygunasekera S, George J. HFE mutations, hepatic iron and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology. 2002;36:142-149.
23. Deguti MM, Sipahi AM, Gayotto LC, Pal cios SA, Bittencourt PL, Goldberg AC, Laudanna AA, Carrilho FJ, Can ado EL. Lack of evidence for the pathogenic role of iron and HFE gene mutations in Brazilian patients with non-alcoholic steatohepatitis. Braz J Med Biol Res. 2003;36:739-745.
24. Koteish A, Diehl AM. Animal models of steatohepatitis. Best Practice & Res Clin Gastroenterol. 2002;16:679-690.
25. Poulson R. Morphological changes of organs after sucrose or fructose feeding. Prog Biochem Pharmacol. 1986;21:104-134.
26. Reaven GM. Insulin resistance, hyperinsulinemia and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med. 1991;90(Suppl 2A):S7-S12.
27. Oron-Herman M, Rosenthal T, Sela BA. Hyperhomocysteinemia as a component of syndrome X. Metabolism. 2003;52:1491-1495.
28. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 2000;23:57-63.
29. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474.
30. Folch J, Iees M, Sloane Stanly GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497-509.
31. Barnes H, Blackstock J. Estimation of lipids in marine animals and tissues: Detailed investigation of the sulphophosphovaniliun method for total lipids. J Exp Marine Biol Ecol. 1973;12:103-118.
32. Bartlett GR. Colorimetric assay methods for free and phosphorylated glyceric acids. J Biol Chem. 1959;234:469-471.
33. Gottfried SP, Rosenberg B. Improved manual spectrophotometric procedure for determination of triglycerides. Clin Chem. 1973;19:1077-1078.
34. Taylor RP, Broccoli AV, Grisham CM. Enzymatic and colorimetric determination of total serum cholesterol. An undergraduate biochemistry laboratory experiment. J Chem Educ. 1978;55:36-64.
35. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalinized liver samples. S Afr J Med Sci. 1968;33:9-11.
36. Masuo K, Mikami H, Ogihara T, Tuck ML. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens. 2001;14:530-538.
37. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Raminez LC, Raskin P. A double-blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens. 1999;12:298-303.
38. Mason RP, Mak IT, Trumbore MO, Mason PE. Antioxidant properties of calcium antagonists related to membrane biophysical interactions. Am J Cardiol 1999;84(4A):16L-22L.
39. Deakin CD, Fagan E, Williams R. Cytoprotective effects of calcium channel blockers. Mechanisms and potential applications in hepatocellular injury. J Hepatol. 1991;12:251-255.
40. Bird GLA, Prach AT, McMahon AD, Forrest JAH, Mills PR, Danesh BJ. Randomised controlled double-blind trial of calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. J Hepatol. 1998;28:194-198.
41. Moises RS, Carvalho CR, Shiota D, Saad MJ. Evidence for a direct effect of captopril on early steps of insulin action in BC3H-1 myocytes. Metabolism. 2003;52:273-278.
42. Bartosz Kedziora J, Bartosz G. Antioxidant and proxidant properties of captopril and enalapril. Free Radic Biol Med. 1997;23:729-735.
43. Aruoma OI, Akanmu D, Cecchini R, Halliwell B. Evaluation of the ability of the angiotensin converting enzyme inhibitor captopril to scavenge reactive species. Chem Biol Interact. 1991;77:303-314.
44. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE. Angiotensin converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001;121:148-155.
45. Yokohoma S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Takusashi Y, Miyokowa N, Nakamura K. Therapeutic efficacy of angiotensin 2 receptor antagonist in patients with nonalcoholic steatohepatits. Hepatology. 2004;40:1222-1225.
46. Schaefer JP, Tam Y, Hasinoff BB, Tawfik Sm Peng Y, Reimche L, Campbell NR. Ferrous sulphate interacts with captopril. Br J Clin Pharmacol. 1998;46:377-381.
47. Hashimoto K, Imai K, Yoshimura S, Ohtaki T. Twelve month studies on the chronic toxicity of captopril in rats. J Toxicol Sci. 1981;Suppl 2:2,15-246.
48. Gardi C, Arezzini B, Fortino V, Comporti M. Effect of free iron on collagen synthesis, cell proliferation and MMP-2 expression in rat hepatic stellate cells. Biochem Pharmacol. 2002;64:1139-1145.
49. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic steatohepatitis: A pilot study. Hepatology. 1996;23:1464-1467.
50. Kim JI, Tsujino T, Fujioka Y, Saito K, Yokoyama M. Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res. 2003;26:307-313.
51. Nagai Y, Nishio Y, Nakamura T, Maegawa H, Kikkawa R, Kashiwagi A. Amelioration of high fructose-induced metabolic derangement of activation of PPARα. Am J Physiol Enclocrinol Metab. 2002;282: E1180-E1190.
52. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 2003;38:123-132.
53. Huan HL, Shaw NS. Role of hypolipidemic drug clofibrate in altering iron regulatory proteins IRP1 and IRP2 activities and hepatic iron metabolism in rats fed a low iron diet. Toxicol Appl Pharmacol. 2002;180:118-128.